

Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.



March 30, 2026

Company name:	Mochida Pharmaceutical Co., Ltd.
Name of representative:	Naoyuki Mochida, Representative Director, President
(Securities code:	4534 Prime Market, TSE)
Inquiries:	Public Relations, Corporate Planning Department
(Telephone:	+81-3-3225-6303)

Notice Regarding the Succession of Manufacturing and Marketing Approval and Asset Acquisition of URECE Tablets

Mochida Pharmaceutical Co., Ltd. (the “Company”) hereby announces that a resolution was adopted by the Board of Directors held on March 30, 2026, whereby the Company resolved to succeed the manufacturing and marketing approval for “URECE Tablets” (hereinafter, the “Product”), for which FUJI YAKUHIN CO., LTD. (Head Office: Saitama-shi, Saitama; President: Masayuki Takayanagi; hereinafter, “FUJI YAKUHIN”) currently holds the manufacturing and marketing approval in Japan, and to acquire assets related to the Product, including intellectual property rights such as patent rights and trademark rights (hereinafter, the “Acquisition”). The Company further announces that it entered into an agreement with FUJI YAKUHIN regarding the Acquisition today.

1. Reason for the Acquisition

The Company has been committed to research and development of innovative pharmaceutical products since its establishment in 1913 thus providing distinctive medicines to the medical community. Currently, the core pharmaceutical business focuses its resources on the targeted areas of cardiovascular medicine, gastroenterology, obstetrics and gynecology, and psychiatry, while also providing treatments for intractable diseases and generic drugs including biosimilars, to meet medical needs. In the cardiovascular field, the Company offers multiple products mainly for the treatment of lifestyle-related diseases such as hyperlipidemia, hypertension, and hyperuricemia, thereby responding to diverse medical needs.

The Product is a therapeutic agent for gout and hyperuricemia discovered and developed by FUJI YAKUHIN. In March 2017, the Company entered into an agreement with FUJI YAKUHIN for the joint development and commercialization of the Product in Japan. In December 2018, FUJI YAKUHIN submitted a manufacturing and marketing approval application for the Product with gout and hyperuricemia as indicated uses, obtained approval in January 2020, and launched the Product in May of the same year. Since the launch, both companies have jointly conducted information provision activities, while the Company has been responsible for distribution operations.

The Company has determined that succeeding the manufacturing and marketing approval for the Product from FUJI YAKUHIN is the optimal approach for ensuring continued and stable provision of the Product to patients and for continuously contributing to healthcare. Accordingly, the Company has decided to acquire the assets related to the Product. Through the Acquisition, the Company will become the marketing authorization holder of the Product and will continue its commercialization and information provision activities.

2. Overview of the Acquisition

(1) Overview of the Product

Product name	·URECE tablets 0.5mg ·URECE tablets 1mg ·URECE tablets 2mg
Generic name	dotinurad
Therapeutic category	·Selective urate reabsorption inhibitor ·Hyperuricemia treatment agent
Package configuration	·URECE tablets 0.5mg: 100 tablets (PTP), 500 tablets (PTP) ·URECE tablets 1mg: 100 tablets (PTP), 500 tablets (PTP), 500 tablets (bulk) ·URECE tablets 2mg: 100 tablets (PTP)
Marketing authorization holder	FUJI YAKUHIN CO., LTD.
Distributor	Mochida Pharmaceutical Co., Ltd.

(2) Operating Results for the Most Recent Fiscal Year

The total net sales of the Product amounted to approximately 4.6 billion yen (the Company's results for the fiscal year ended March 2025).

(3) Assets Related to the Product

The assets related to the Product are expected to be recorded as intangible assets. No liabilities are associated with the assets.

(4) Acquisition Price

The acquisition price is 13.5 billion yen.

3. Overview of the Counterparty

(1)	Name	FUJI YAKUHIN CO., LTD.	
(2)	Location	4-383 Sakuragicho, Omiya-ku, Saitama-shi, Saitama	
(3)	Job title and name of representative	Masayuki Takayanagi, President and Representative Director	
(4)	Description of business	Household Distribution, Drug Store and Dispensing Pharmacy, Manufacturing, Medical Pharmaceutical Sales	
(5)	Share capital	100 million yen	
(6)	Date of establishment	April, 1954	
(7)	Relationship between the Company and said company	Capital relationship	None
		Personnel relationship	None
		Business relationship	FUJI YAKUHIN has entered into an agreement with the Company regarding the joint development and commercialization of the Product.
		Related party relationship	None

4. Timetable

(1)	Date of resolution at the meeting of the Board of Directors	March 30, 2026
(2)	Date of conclusion of the agreement	March 30, 2026
(3)	Scheduled date of the execution of the Acquisition	June 30, 2026 (scheduled)
(4)	Date of succession of manufacturing and marketing approval	Scheduled to be completed following the necessary procedures with the Ministry of Health, Labour and Welfare.

5. Future Outlook

The assets related to the Product will be recorded as intangible fixed assets. As the scheduled execution date of the Acquisition falls in the next consolidated fiscal year, there will be no impact on the consolidated financial results for the fiscal year ending March 2026. The consolidated earnings forecast for the fiscal year ending March 2027 will be announced at the time of the earnings release for the fiscal year ending March 2026, scheduled for May of this year.

6. Other

The Company and FUJI YAKUHIN have entered into a manufacturing outsourcing agreement under which FUJI YAKUHIN will continue to manufacture the Product and supply it to the Company.

###